Autor(es): Rocha, C ; Afonso, J ; Lago, P ; Arroja, B ; Vieira, AI ; Dias, CC ; Magro, F
Data: 2019
Identificador Persistente: http://hdl.handle.net/10400.23/1323
Origem: Repositório Científico do Hospital de Braga
Assunto(s): Adalimumab
Autor(es): Rocha, C ; Afonso, J ; Lago, P ; Arroja, B ; Vieira, AI ; Dias, CC ; Magro, F
Data: 2019
Identificador Persistente: http://hdl.handle.net/10400.23/1323
Origem: Repositório Científico do Hospital de Braga
Assunto(s): Adalimumab
The loss of response to adalimumab (ADL) has been related to low serum concentrations at trough. Currently, most methods commercially available for the quantification of ADL are enzyme-linked immunosorbent assay (ELISA) based, with a turnaround time of approximately 8 h, delaying the target dosage adjustment to the subsequent infusion. In this study, we aimed to evaluate the performance of the newly available rapid-test ADL quantification assay by comparing it with three established ELISA methods, using spiked samples and a set of clinical samples.